- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02186223
The Angel® Catheter Pivotal Clinical Trial
February 17, 2017 updated by: BiO2 Medical
The Angel® Catheter Clinical Trial: Prevention of Pulmonary Embolism in High Risk Subjects
The primary objective of this multicenter, prospective, single arm clinical trial is to evaluate the safety and effectiveness of the Angel® Catheter in subjects at high risk of PE, and with recognized contraindications to standard pharmacological therapy (anticoagulation).
Study Overview
Status
Completed
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
172
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Los Angeles, California, United States, 90048
- Cedars-Sinai Medical Center
-
San Diego, California, United States, 92103
- UC San Diego Medical Center
-
-
Colorado
-
Loveland, Colorado, United States, 80538
- Medical Center of the Rockies
-
-
Florida
-
Delray Beach, Florida, United States, 33483
- Delray Medical Center
-
Ft. Lauderdale, Florida, United States, 33316
- Broward Health Medical Center
-
Gainesville, Florida, United States, 32608
- UF Health Shands Cancer Hospital
-
Miami, Florida, United States, 33136
- Jackson Memorial Hospital
-
West Palm Beach, Florida, United States, 33407
- St. Mary's Medical Center
-
-
Maryland
-
Baltimore, Maryland, United States, 21201
- University of Maryland Medical Center
-
-
Missouri
-
St. Louis, Missouri, United States, 63141
- Mercy Hospital St. Louis
-
-
New Jersey
-
Camden, New Jersey, United States, 08103
- Cooper University Hospital
-
-
New Mexico
-
Albuquerque, New Mexico, United States, 87106
- University of New Mexico Health
-
-
New York
-
New York, New York, United States, 10029
- Mount Sinai Hospital
-
-
North Carolina
-
Winston-Salem, North Carolina, United States, 27157
- Wake Forest Baptist Health
-
-
Pennsylvania
-
Bethlehem, Pennsylvania, United States, 18015
- St. Luke's University Health Network
-
-
South Carolina
-
Charleston, South Carolina, United States, 29425
- Medical University of South Carolina
-
-
Tennessee
-
Memphis, Tennessee, United States, 38103
- Regional One Health
-
Nashville, Tennessee, United States, 37232
- Vanderbilt University Medical Center
-
-
Texas
-
Fort Worth, Texas, United States, 76104
- John Peter Smith Health Network
-
Houston, Texas, United States, 77030
- Ben Taub Hospital
-
San Antonio, Texas, United States, 78229
- University of Texas Health Science Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Subject or legally authorized representative is willing and able to provide written informed consent,
- Subject is 18 years or older,
Subject is expected to remain in a critical care setting for at least 72 hours,
AND at least one of the following inclusion criteria (4,5, and/or 6)
Subject has recognized contraindications to standard pharmacological thromboprophylaxis including:
- Active bleeding or at high risk for bleeding OR
- Hypersensitivity to pharmacological thromboprophylaxis OR
- History of severe heparin induced thrombocytopenia OR
- Severe thrombocytopenia
- Subject has a confirmed acute proximal lower extremities DVT or a confirmed acute PE with recognized contraindication to anticoagulation
- Subject requires a temporary interruption (>24 hours) of pharmacological thromboprophylaxis for a surgical or medical procedure
Exclusion Criteria:
- Subject is pregnant
- Subject is in treatment with an investigational drug or device within 30 days prior to enrollment
- Subject has a pre-existing IVC filter in place
- BMI = > 45
- Subject has functioning pelvic renal allograft on the only side available for device insertion
- Subject has undergone a surgical procedure involving the femoral vein or pelvic veins through which the device must be inserted
- Anatomic inability to place the Angel® Catheter
- Subject has known hypersensitivity to any of the components of the Angel® Catheter, specifically Nitinol (nickel and/or titanium)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: The Angel® Catheter
All eligible subjects will receive an Angel® Catheter.
|
The Angel® Catheter is a temporary device that combines the functions of an inferior vena cava (IVC) filter and a 3-lumen central venous catheter (CVC).
The device can be placed at the bedside into the inferior vena cava via the femoral vein for the prevention of Pulmonary Embolism (PE) and for access to the central venous system.
The device is intended for short-term (less than 30 days) vascular access via the femoral vein.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Freedom From Clinically Significant PE or Fatal PE During Treatment Period
Time Frame: Assessed daily from Baseline through Study Exit which occurs 3 days post-Angel Catheter Removal OR at hospital discharge, whichever is first (maximum of 33 assessment days with an anticipated average of 7 days)
|
|
Assessed daily from Baseline through Study Exit which occurs 3 days post-Angel Catheter Removal OR at hospital discharge, whichever is first (maximum of 33 assessment days with an anticipated average of 7 days)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of Acute Proximal Deep Vein Thrombosis
Time Frame: Assessed daily from Baseline through Study Exit which occurs 3 days post-Angel Catheter Removal OR at hospital discharge, whichever occurs first (maximum of 33 assessment days with an anticipated average of 7 days)
|
Assessed daily from Baseline through Study Exit which occurs 3 days post-Angel Catheter Removal OR at hospital discharge, whichever occurs first (maximum of 33 assessment days with an anticipated average of 7 days)
|
|
Incidence of Catheter Related Thrombosis
Time Frame: Assessed daily from Baseline through Study Exit which occurs 3 days post-Angel Catheter Removal OR at hospital discharge, whichever occurs first (maximum of 33 assessment days with an anticipated average of 7 days)
|
Assessed daily from Baseline through Study Exit which occurs 3 days post-Angel Catheter Removal OR at hospital discharge, whichever occurs first (maximum of 33 assessment days with an anticipated average of 7 days)
|
|
Incidence of Catheter Related Blood Stream Infections
Time Frame: Assessed daily from Baseline through Study Exit which occurs 3 days post-Angel Catheter Removal OR at hospital discharge, whichever occurs first (maximum of 33 assessment days with an anticipated average of 7 days)
|
Assessed daily from Baseline through Study Exit which occurs 3 days post-Angel Catheter Removal OR at hospital discharge, whichever occurs first (maximum of 33 assessment days with an anticipated average of 7 days)
|
|
Incidence of Major Bleeding Event
Time Frame: Assessed daily from Baseline through Study Exit which occurs 3 days post-Angel Catheter Removal OR at hospital discharge, whichever occurs first (maximum of 33 assessment days with an anticipated average of 7 days)
|
Assessed daily from Baseline through Study Exit which occurs 3 days post-Angel Catheter Removal OR at hospital discharge, whichever occurs first (maximum of 33 assessment days with an anticipated average of 7 days)
|
|
Incidence of PEs Averted
Time Frame: During the pre-removal cavogram (An average of 6.8 days after device insertion)
|
During the pre-removal cavogram, the presence of significant clot (>25% of the volume of the filter) trapped by the Angel® Catheter will be assessed.
The number of subjects with significant clot trapped by the device will be reported as the number of PEs averted.
|
During the pre-removal cavogram (An average of 6.8 days after device insertion)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Victor Tapson, MD, Cedars Sinai
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 1, 2015
Primary Completion (Actual)
December 1, 2015
Study Completion (Actual)
December 1, 2015
Study Registration Dates
First Submitted
July 7, 2014
First Submitted That Met QC Criteria
July 9, 2014
First Posted (Estimate)
July 10, 2014
Study Record Updates
Last Update Posted (Actual)
April 4, 2017
Last Update Submitted That Met QC Criteria
February 17, 2017
Last Verified
February 1, 2017
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- QD-230
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Trauma
-
Humacyte, Inc.Active, not recruitingTrauma | Trauma Injury | Trauma, Multiple | Trauma BluntUkraine
-
Prof. Dr. Cemil Tascıoglu Education and Research...CompletedTrauma Injury | Trauma, MultipleTurkey
-
Wonju Severance Christian HospitalNational Research Foundation of KoreaRecruitingTrauma Injury | Trauma, MultipleKorea, Republic of
-
Rabin Medical CenterIsraeli Ministry of SecurityUnknown
-
University Hospital, AngersRecruiting
-
Chang, Steve S., M.D.Santa Barbara Cottage Hospital; Accumetrics, Inc.CompletedHead Injury Trauma BluntUnited States
-
Oslo University HospitalUniversity of Oslo; Sunnaas Rehabilitation Hospital; South-Eastern Norway Regional...RecruitingTrauma Injury | Trauma, Multiple | PolytraumaNorway
-
Assistance Publique - Hôpitaux de ParisFrancophone Pediatric Resuscitation and Emergency Group (GFRUP)Completed
-
Fundacion Clinica Valle del LiliUniversity of Pittsburgh; Hospital Universitario del Valle Evaristo GarciaRecruitingTrauma | Trauma Injury | Trauma, MultipleColombia
Clinical Trials on The Angel® Catheter
-
BiO2 MedicalTerminatedDeep Vein Thrombosis | Venous Thromboembolism | Pulmonary EmbolismUnited States
-
BiO2 MedicalUnknownDeep Vein Thrombosis | Pulmonary Embolism | Catheter-related Bloodstream Infection (CRBSI) Nos | Medical Device Complication | Catheter ThrombosisUnited Kingdom, Germany, Italy
-
BiO2 MedicalCompletedDeep Vein Thrombosis | Venous Thromboembolism | Pulmonary EmbolismColombia
-
University of California, San DiegoRecruitingOsteo Arthritis KneeUnited States
-
Matthew PingreeActive, not recruitingLumbar SpondylosisUnited States
-
Acandis GmbHTerminatedAcute Ischemic Stroke | Intracranial StenosisGermany
-
Hospital Universitari de BellvitgeAsociacion Española de Coloproctologia; Asociación Española de CirugíaRecruitingLow Anterior Resection SyndromeSpain
-
Vascular Solutions LLCBright Research Partners; TeleflexCompletedIschemic Heart Disease | Chronic Total Occlusion | Chronic Total Occlusion of Coronary ArteryUnited States
-
Princess Al-Johara Al-Ibrahim Cancer Research CenterCompletedProstatic ObstructionSaudi Arabia
-
Scott Martin Miller, MDBiosense Webster, Inc.Terminated